Vir Biotechnology Inc.

8 trials 3 recruiting Commercial sponsor

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

3 Recruiting

5 Completed trials

10 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase III: 2 Phase II: 4 Phase I: 2

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hepatitis D 4 Chronic hepatitis B 2 Hormone-refractory prostate cancer 1

Top IMPs

ELEBSIRAN 6 TOBEVIBART 6 BULEVIRTIDE 2 PEGINTERFERON ALFA-2A 2 TENOFOVIR DISOPROXIL 1

All trials

8 total

A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide Recruiting

2024-519282-22-00 Phase III 6 countries BULEVIRTIDE; ELEBSIRAN; TOBEVIBART
Safety, pharmacokinetics, and preliminary efficacy of VIR-5500 (AMX-500) in prostate cancer Recruiting

2023-503495-24-00 Phase I 1 country
A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic… Recruiting

2024-516010-38-00 Phase I 3 countries
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended

2024-520062-54-00 Phase II 8 countries BULEVIRTIDE; ELEBSIRAN; TOBEVIBART
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Ended

2024-515919-22-00 Phase III 3 countries ELEBSIRAN; TOBEVIBART
A Study to Evaluate Investigational Therapies in Chronic Hepatitis D Virus Infection. Ended

2024-512203-40-00 Phase II 6 countries ELEBSIRAN; TOBEVIBART
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects wi… Ended

2024-513177-48-00 Phase II 2 countries ELEBSIRAN; PEGINTERFERON ALFA-2A; TOBEVIBART
A Study to Evaluate Investigational Therapies in Chronic Hepatitis B Virus Infection Ended

2024-513176-17-00 Phase II 2 countries ELEBSIRAN; PEGINTERFERON ALFA-2A; TENOFOVIR DISOPROXIL; TOBEVIBART

Showing 1–8 of 8 trials

← All sponsors A–Z